Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.51 |
| ▸ | XIAP | P98170 | 12/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252827 | 1.00 | CASP1 (0.51) | CASP1XIAPCYP3A4CASP3MAPK1 | |
| SCHEMBL10249455 | 0.94 | CASP1 (0.51) | CASP1XIAPCYP3A4CASP3MAPK1 | |
| SCHEMBL10200079 | 0.94 | CASP1 (0.51) | CASP1XIAPCYP3A4CASP3MAPK1 | |
| SCHEMBL13140309 | 0.90 | CASP1 (0.46) | CASP1XIAPCYP3A4 | |
| SCHEMBL10263215 | 0.86 | CASP1 (0.46) | CASP1XIAPCYP3A4MAPK1TSHR | |
| SCHEMBL10285165 | 0.86 | CASP1 (0.46) | CASP1XIAPCYP3A4MAPK1TSHR | |
| SCHEMBL10249494 | 0.86 | CASP1 (0.56) | CASP1XIAPCYP3A4CASP3 | |
| SCHEMBL10201798 | 0.86 | CASP1 (0.56) | CASP1XIAPCYP3A4CASP3 | |
| SCHEMBL10201769 | 0.85 | CASP1 (0.68) | CASP1XIAPCYP3A4CASP3 | |
| SCHEMBL12444062 | 0.85 | CASP1 (0.68) | CASP1XIAPCYP3A4CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885XIAP 257/4885CYP3A4 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.